Scarica l'app Stockscreener
12.95
12.51%
1.44
Precedente Chiudi:
$11.51
Aprire:
$11.935
Volume 24 ore:
1.22M
Relative Volume:
1.77
Capitalizzazione di mercato:
$852.29M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+19.69%
1M Prestazione:
+48.34%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.82
$13.12
Intervallo di 1 settimana:
$10.81
$13.12
Portata 52W:
$5.33
$13.12
Niagen Bioscience Inc Stock (NAGE) Company Profile
Nome
Niagen Bioscience Inc
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Confronta NAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
12.95 | 852.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Niagen Bioscience (NASDAQ:NAGE) Cut to "Buy" at Wall Street Zen - MarketBeat
Niagen Bioscience (NAGE) Receives Price Target Boost from Roth Capital | NAGE Stock News - GuruFocus
Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $23.00 - MarketBeat
What 4 Analyst Ratings Have To Say About Niagen Bioscience - Nasdaq
Niagen Bioscience (NASDAQ:NAGE) Shares Gap UpTime to Buy? - MarketBeat
Niagen Bioscience (NAGE) Target Price Raised to $23 by Roth Capi - GuruFocus
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript - MSN
Niagen Bioscience (NASDAQ:NAGE) Shares Up 8.2%Time to Buy? - MarketBeat
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consum - GuruFocus
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference | NAGE Stock News - GuruFocus
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference - Business Wire
Niagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year HighHere's Why - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Now Covered by Canaccord Genuity Group - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Canaccord Genuity Initiates Coverage of Niagen Bioscience (NAGE) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target - marketscreener.com
Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’ - TipRanks
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Pric - GuruFocus
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Price Target | NAGE Stock News - GuruFocus
Canaccord Analyst Recommends Buying Niagen Bioscience (NAGE) Stock | NAGE Stock News - GuruFocus
Niagen Bioscience: Overbought After Rally (NASDAQ:NAGE) - Seeking Alpha
3 Stocks That May Be Trading Below Their Estimated Value - simplywall.st
Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month HighHere's Why - MarketBeat
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Niagen Bioscience Reaches Analyst Target Price - Nasdaq
Ratios Uncovered: Breaking Down Niagen Bioscience Inc (NAGE)’s Trailing Twelve Months Metrics - DWinneX
Niagen Bioscience: Q1 Earnings Snapshot - New Haven Register
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook - BioSpace
Niagen Bioscience Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Niagen Bioscience Q1 2025 sales surge, stock rises - Investing.com Nigeria
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings: EPS of $0.07 Beats Estimate, Revenue Surges to $30.5 Million - GuruFocus
Niagen Bioscience (NAGE) Reports Record Q1 Revenue with Strong G - GuruFocus
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Niagen Bioscience Q1 2025 slides: revenue jumps 38%, raises full-year outlook - Investing.com
Niagen Bioscience, Inc. SEC 10-Q Report - TradingView
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 | NAGE Stock News - GuruFocus
What's Next: Niagen Bioscience's Earnings Preview - Nasdaq
Niagen Bioscience Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Niagen Bioscience (NAGE) Expands Clinical Network with New Clinics - GuruFocus
Niagen IV therapy expands to nearly 600 clinics nationwide By Investing.com - Investing.com India
Niagen IV therapy expands to nearly 600 clinics nationwide - Investing.com
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide | NAGE Stock News - GuruFocus
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide - Nasdaq
Three High Growth Companies Insiders Are Eager To Hold - Yahoo Finance
Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari
Non sono disponibili dati finanziari per Niagen Bioscience Inc (NAGE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Niagen Bioscience Inc Azioni (NAGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):